Oncolytic Viruses Development And cGMP Manufacturing − Experience Matters

GettyImages-1306664598 lab research

Oncolytic viruses (OVs) are natural or recombinant attenuated versions of common viruses that do not cause disease but instead infect tumor cells preferentially over healthy cells. The virus eventually kills infected cells, which releases molecular and cell-derived fragments that stimulate an immune response against the remaining cancerous tissue. This overall combined effect can occur with no prior knowledge of the cancer, its response to conventional treatments, or its specific antigenic composition.

OVs utilize a variety of viruses and vectors under current research and clinical trial – although limited commercial approvals exist to date. In this article, understand more about the leading OVs, the leading cell lines, and how to strategize your oncolytic virus production plan.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Outsourced Pharma

FUJIFILM Diosynth Biotechnologies